In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and ...

The regulator cleared Tecartus (brexucabtagene autoleucel) for the new indication after a swift review that focused on the ZUMA-3 trial, which showed that 65% of patients treated with the CAR-T ...

Tecartus is also being tested in paediatric and adolescent patients with previously-treated ALL in the ZUMA-4 study, which would put the two therapies in direct contention. However, results from ...

CD19-directed autologous CAR T cell therapies such as Gilead's (NASDAQ:GILD) Yescarta and Tecartus, Bristol Myers' (BMY) Breyanzi, and Novartis (NYSE:NVS) (OTCPK:NVSEF) Kymriah are also included ...

The oncology portfolio, including Trodelvy, Yescarta, and Tecartus, showed remarkable growth, reflecting increasing demand in relevant treatment areas. HIV Portfolio Performance: Biktarvy ...